Prostate cancer vaccines in combination with additional treatment modalities

被引：15
|
作者：
Uhlman, Matthew A. [1 ]
Bing, Megan T. [1 ]
Lubaroff, David M. [1 ,2 ,3 ]
机构：
[1] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA
[3] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
来源：
IMMUNOLOGIC RESEARCH | 2014年 / 59卷 / 1-3期
关键词：
Prostate cancer; Immunotherapy; Cancer vaccines; Combination therapy; AUTOLOGOUS CELLULAR IMMUNOTHERAPY; SIPULEUCEL-T; IMMUNOSTIMULATORY PROPERTIES; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; RADIATION-THERAPY; ACID-PHOSPHATASE; DOUBLE-BLIND; PHASE-II; DOCETAXEL;
D O I：
10.1007/s12026-014-8532-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Immunotherapy has been investigated in both preclinical studies and clinical trials as a new therapy for prostate cancer. Vaccines, including those that utilize dendritic cells, viruses, or DNA, immunize against prostate-specific antigen and prostatic acid phosphatase. The vaccines have long been studied as monotherapy for the cancer, but increasingly more trials have been initiated in combination with other modalities. These include radiation, chemotherapy, and androgen deprivation therapy. This review describes and discusses the various combinations of vaccine immunotherapies.
引用
收藏
页码：236 / 242
页数：7
相关论文
共 50 条
  • [21] From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer
    Madan, Ravi A.
    Aragon-Ching, Jeanny B.
    Gulley, James L.
    Dahut, William L.
    EXPERT REVIEW OF VACCINES, 2011, 10 (06) : 743 - 753
  • [22] New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
    van Dodewaard-de Jong, Joyce M.
    Verheul, Henk M. W.
    Bloemendal, Haiko J.
    de Klerk, John M. H.
    Carducci, Michael A.
    van den Eertwegh, Alfons J. M.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 271 - 279
  • [23] Androgen deprivation and immunotherapy for the treatment of prostate cancer
    Gamat, Melissa
    McNeel, Douglas G.
    ENDOCRINE-RELATED CANCER, 2017, 24 (12) : T297 - T310
  • [24] Recent advances in immunotherapy for the treatment of prostate cancer
    Sonpavde, Guru
    Agarwal, Neeraj
    Choueiri, Toni K.
    Kantoff, Philip W.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (08) : 997 - 1009
  • [25] Patient reported outcomes among treatment modalities for prostate cancer
    Johnson, Matthew E.
    Zaorsky, Nicholas G.
    Martin, Jeffrey M.
    Ruth, Karen
    Greenberg, Richard E.
    Uzzo, Robert G.
    Hayes, Shelly B.
    Smaldone, Marc C.
    Kutikov, Alexander
    Viterbo, Rosalia
    Chen, David Y. T.
    Hallman, Mark A.
    Sobczak, Mark L.
    Horwitz, Eric M.
    CANADIAN JOURNAL OF UROLOGY, 2016, 23 (06) : 8535 - 8545
  • [26] Prospects for the future of prostate cancer vaccines
    Madan, Ravi A.
    Gulley, James L.
    EXPERT REVIEW OF VACCINES, 2016, 15 (03) : 271 - 274
  • [27] Immunotherapy in Prostate Cancer
    Fay, Emily K.
    Graff, Julie N.
    CANCERS, 2020, 12 (07) : 1 - 17
  • [28] Neoadjuvant and adjuvant treatment modalities for prostate cancer
    Erkan, Erkan
    Toktas, Gokhan
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (02): : 63 - 69
  • [29] Sequencing Treatment for Castration-Resistant Prostate Cancer
    Handy, Catherine E.
    Antonarakis, Emmanuel S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
  • [30] Targeted nanomedicine modalities for prostate cancer treatment
    Cohen, Lital
    Livney, Yoav D.
    Assaraf, Yehuda G.
    DRUG RESISTANCE UPDATES, 2021, 56
12345